Efficacy Study of Risedronate to Prevent Cancer Treatment-Induced Bone Loss in Prostate Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

January 31, 2009

Study Completion Date

February 28, 2009

Conditions
Prostate Cancer
Interventions
DRUG

risedronate

risedronate 35mg tablet, weekly for 12 months

DRUG

risedronate

35mg weekly

DRUG

Control

risedronate-matched placebo weekly

Trial Locations (21)

V1Y 2H4

Southern Interior Medical Research Corporation, Kelowna

V3V 1N1

Dr. Cal Andreou, Surrey

E3B 5B8

Dr. Allan Patrick, Fredericton

L4M 7G1

The Male/Female Health and Research Centre, Barrie

L6T 3J1

Dr. Stanley Flax, Brampton

N3R 4N3

Brantford Urology Research, Medical Arts Building, Brantford

L7N 3V2

G. Kenneth Jansz Medicine Professional Corporation, Burlington

L7S 1V2

Urology Research Centre, Burlington

P3E 4T3

Northern Urology Centre, Greater Sudbury

N1H 5J1

Guelph Urology Associates, Guelph

L5M 4N4

Credit Valley Medical Arts Centre, Mississauga

L3X 1W1

Mor Urology Inc., Bayview Business Centre, Newmarket

L6H 3P1

The Male and Female Health Centre, Oakville

L3V 7V1

Orillia Urology Associates, Orillia

L1H 1B9

Urotec, Oshawa

N4K 2J1

Dr. Todd Webster, Owen Sound

K9H 1T6

Kawartha Urology Associates, Peterborough

M1S 4V5

Dr. Allan Abramovitch, Scarborough Village

M6A 3B5

The Male Health Centre, Toronto

M2K 2W1

Dr. Roger J. Buckley, Willowdale

J4V 2H3

Urology South Shore Research, Greenfield Park

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

CMX Research

OTHER